FOR the first time in decades, a new class of medication, Cobenfy (formerly KarXT), has been approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia.
Monash University scientists have played a key role in the development of Cobenfy over the past 30 years.
The Bristol Myers Squibb's and Karuna Therapeutics' drug, a combination of xanomeline and trospium, works to improve symptoms of schizophrenia while reducing debilitating side effects.
"Cobenfy represents a whole new class of more targeted medicines," said lead researcher, Prof Arthur Christopoulos, Dean of the Faculty of Pharmacy and Pharmaceutical Sciences at Monash University.
"This is a major advancement in the treatment of schizophrenia and other difficult neuropsychiatric diseases," Christopoulos said.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Sep 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Sep 24
